Robert S. Radie

Robert Radie has served as a Director on the Board since March 2020.

Mr. Radie has more than three decades of industry experience, working in both public and private pharmaceutical and biotech companies across a range of therapeutic areas. He has held senior executive positions in several companies, including serving as Chief Executive Officer of Zyla Life Sciences, Topaz Pharmaceuticals, Inc., and Transmolecular, Inc. Mr. Radie also served as Chief Business Officer at Prestwick Pharmaceuticals, Inc., Morphotek, Inc., and Senior Vice President of Strategy and Planning at Vicuron Pharmaceuticals, Inc. Mr. Radie began his career at Eli Lilly and Company, where he worked for 18 years in sales and marketing positions with increasing levels of responsibility.

Mr. Radie holds several Board positions, including Paratek Pharmaceuticals, a public biopharmaceutical company; LPSA, the Pennsylvania industry advocacy group; and Horse Power for Life, a non-profit organization dedicated to improving the quality of life for individuals diagnosed with cancer. He previously served on the Boards of Veloxis Pharmaceuticals and Affinium Pharmaceuticals, a private specialty pharmaceutical company.

Mr. Radie received his B.S. in Chemistry from Boston College.